Literature DB >> 8536524

Intraluminal excretion of PAF, lysoPAF, and acetylhydrolase in patients with ulcerative colitis.

R Guimbaud1, A Izzo, J P Martinolle, N Vidon, D Couturier, J Benveniste, S Chaussade.   

Abstract

PAF-acether (PAF) is a phospholipid synthesized by numerous inflammatory cells. PAF can produce several pathological changes in various organs, especially in the colon. In animals PAF causes colonic ulceration and inflammation, which are similar to the anatomic lesions seen in human ulcerative colitis. The aim of this study was to measure in vivo colonic production of PAF in active ulcerative colitis using a modified colonic perfusion method. Ten patients with active ulcerative colitis and six control patients were investigated. A colonic segment was continuously perfused with a buffer and the liquid was recovered 20 cm distally, after a 45-min period of equilibration, at 20-min intervals. PAF, lysoPAF, and acetylhydrolase were measured in the colonic samples. PAF and lysoPAF outputs were significantly higher in patients with active ulcerative colitis compared to controls patients. There was a significant correlation between colonic PAF output and, respectively, macroscopic mucosal lesions and myeloperoxidase colonic output. We thus conclude: (1) the colonic perfusion method allows in vivo study of the metabolism of PAF during ulcerative colitis and could also be used to study the efficiency of PAF antagonists in UC; and (2) colonic production of PAF is increased during ulcerative colitis and correlated to local injury and inflammation. Whether or not PAF plays a role in the pathogenesis of ulcerative colitis remains open for further investigations.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8536524     DOI: 10.1007/bf02220453

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  26 in total

1.  Bowel necrosis induced by tumor necrosis factor in rats is mediated by platelet-activating factor.

Authors:  X M Sun; W Hsueh
Journal:  J Clin Invest       Date:  1988-05       Impact factor: 14.808

2.  The assay of catalases and peroxidases.

Authors:  A C MAEHLY; B CHANCE
Journal:  Methods Biochem Anal       Date:  1954

3.  Effects of topical 5-aminosalicylic acid and prednisolone on prostaglandin E2 and leukotriene B4 levels determined by equilibrium in vivo dialysis of rectum in relapsing ulcerative colitis.

Authors:  K Lauritsen; L S Laursen; K Bukhave; J Rask-Madsen
Journal:  Gastroenterology       Date:  1986-10       Impact factor: 22.682

4.  Hypoxia causes ischemic bowel necrosis in rats: the role of platelet-activating factor (PAF-acether).

Authors:  M S Caplan; X M Sun; W Hsueh
Journal:  Gastroenterology       Date:  1990-10       Impact factor: 22.682

5.  Intestinal epithelial cells contribute to the enhanced generation of platelet activating factor in ulcerative colitis.

Authors:  L Ferraris; F Karmeli; R Eliakim; J Klein; C Fiocchi; D Rachmilewitz
Journal:  Gut       Date:  1993-05       Impact factor: 23.059

6.  Catabolism of platelet-activating factor by human colonic mucosa. Calcium dependence of the catabolizing enzymes.

Authors:  C B Appleyard; K Hillier
Journal:  Biochem Pharmacol       Date:  1992-06-23       Impact factor: 5.858

7.  Neutrophil mucosal involvement is accompanied by enhanced local production of interleukin-8 in ulcerative colitis.

Authors:  Y Raab; B Gerdin; S Ahlstedt; R Hällgren
Journal:  Gut       Date:  1993-09       Impact factor: 23.059

8.  Phase II study of the safety and efficacy of a 5-lipoxygenase inhibitor in patients with ulcerative colitis.

Authors:  C Collawn; P Rubin; N Perez; J Bobadilla; G Cabrera; E Reyes; J Borovoy; D Kershenobich
Journal:  Am J Gastroenterol       Date:  1992-03       Impact factor: 10.864

9.  Potent ulcerogenic actions of platelet-activating factor on the stomach.

Authors:  A C Rosam; J L Wallace; B J Whittle
Journal:  Nature       Date:  1986 Jan 2-8       Impact factor: 49.962

10.  PAF-acether and acetylhydrolase in stool of patients with Crohn's disease.

Authors:  Y Denizot; S Chaussade; N Nathan; J F Colombel; M J Bossant; N Cherouki; J Benveniste; D Couturier
Journal:  Dig Dis Sci       Date:  1992-03       Impact factor: 3.199

View more
  3 in total

Review 1.  Prolonged-release mesalazine: a review of its therapeutic potential in ulcerative colitis and Crohn's disease.

Authors:  D Clemett; A Markham
Journal:  Drugs       Date:  2000-04       Impact factor: 9.546

Review 2.  Key role of mast cells and their major secretory products in inflammatory bowel disease.

Authors:  Shao-Heng He
Journal:  World J Gastroenterol       Date:  2004-02-01       Impact factor: 5.742

3.  Host Metabolic Response in Early Lyme Disease.

Authors:  Bryna L Fitzgerald; Claudia R Molins; M Nurul Islam; Barbara Graham; Petronella R Hove; Gary P Wormser; Linden Hu; Laura V Ashton; John T Belisle
Journal:  J Proteome Res       Date:  2020-01-09       Impact factor: 4.466

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.